VHH POLYPEPTIDES THAT BIND TO LIGHT CHAIN (LC) PROTEASES OF BOTULINUM NEUROTOXINS (BoNTs) AND METHODS OF USE THEREOF
AssigneeTrustees of Tufts College
InventorCharles B. SHOEMAKER
Life of this patent
Estimating the term…
Loading patent…
AssigneeTrustees of Tufts College
InventorCharles B. SHOEMAKER
Estimating the term…
Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC/A and BoNT LC/B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC/A toxin-binding and LC/B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.
A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B), or a LC/B-binding portion thereof,
A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B) or a LC/B-binding portion thereof, wherein the VHH polypeptide that binds to the LC/A toxin comprises an amino acid sequence having at least 85% sequence identity to an amino acid sequence of an LC/A-binding polypeptide selected from the group consisting of JPU-A1 as set forth in SEQ ID NO:
A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B) or a LC/B-binding portion thereof, wherein the VHH polypeptide that binds to LC/A comprises or consists of JPU-A1 as set forth in SEQ ID NO:
The method of 23, further comprising administering to the subject an anti-epitope tag antibody that specifically binds to an epitope tag, if present, and facilitates clearance of a complex of LC/A and/or LC/B bound to the anti-LC/A and/or anti-LC/B VHH polypeptide from the subject.
The method of 24, further comprising administering to the subject an anti-epitope tag antibody that specifically binds to an epitope tag, if present, and facilitates clearance of a complex of LC/A and/or LC/B bound to the anti-LC/A and/or anti-LC/B VHH polypeptide from the subject.
Dependencies are inferred from the claim text.